IL2 and plasma cell myeloma: The clinical benefit observed in terms of TTP does not support the use of maintenance treatment with IL2/zoledronate such as treatment options in myeloma patients after autologous bone marrow transplantation, especially after that lenalidomide has become the stranded of care.